Sera Prognostics Q1 revenue $100K, net loss $10.6M; AVERT trial positive

SERA PROGNOSTICS, INC.

2023-Q1 EPS reported -$0.34 revenue$100,000

Revenue $100K, up 163% from $38K in Q1 2022.
Net loss narrowed to $10.6M from $12.2M YoY.
Cash and securities $100M; R&D spend $4.1M (up), SG&A $7.3M (down).
Positive AVERT PRETERM TRIAL topline results announced in February.
Physician orders increasing; PRIME study interim look expected by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

SERA PROGNOSTICS, INC. reported the first quarter of 2023 ended March 31, 2023 results: revenue $100,000, net income $10.6 million loss.

Period: the first quarter of 2023 ended March 31, 2023
Revenue: $100,000
Net income: $10.6 million loss
Result: reported results

Exact text from the filing

should serve as an additional catalyst to help us expand the use of our PreTRM Test and to increase revenue.” First Quarter 2023 Financial Results First quarter 2023 revenue of $100,000 compared to $38,000 for the same period of 2022. Total operating expenses were $11.4 million, down from $12.3 million for the first quarter of 2022. Research and development

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SERA PROGNOSTICS, INC. filing history →

Source: SEC EDGAR

accession 0001534969-23-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.